View in EDS

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.

Saved in:
Bibliographic Details
Title: A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
Authors: de Winter, Robbert J., Yuki Katagiri, Asano, Taku, Milewski, Krzysztof P., Lurz, Philipp, Buszman, Pawel, Jessurun, Gillian A. J., Koch, Karel T., Troquay, Roland P. T., Hamer, Bas J. B., Ophuis, Ton Oude, Wöhrle, jochen, Wyderka, Rafal, Cayla, Guillaume, Hofma, Sjoerd H., Levesque, Sébastien, Żurakowski, Aleksander, Fischer, Dieter, Kośmider, Maciej, Goube, Pascal
Source: Lancet. 2/3/2018, Vol. 391 Issue 10119, p431-440. 10p.
Subjects: Drug-eluting stents, Surgical stents, Clinical trials, Randomized controlled trials, Coronary disease, Rapamycin, Cardiovascular system, Comparative studies, Immunosuppressive agents, Longitudinal method, Research methodology, Medical care, Medical cooperation, Myocardial infarction, Research, Statistical sampling, Evaluation research, Treatment effectiveness, Blind experiment, Acute coronary syndrome
Abstract: Background: MiStent is a drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall. It was developed to overcome the limitation of current durable polymer drug-eluting stents eluting amorphous sirolimus. The clinical effect of MiStent sirolimus-eluting stent compared with a durable polymer drug-eluting stents has not been investigated in a large randomised trial in an all-comer population.Methods: We did a randomised, single-blind, multicentre, phase 3 study (DESSOLVE III) at 20 hospitals in Germany, France, Netherlands, and Poland. Eligible participants were any patients aged at least 18 years who underwent percutaneous coronary intervention in a lesion and had a reference vessel diameter of 2·50-3·75 mm. We randomly assigned patients (1:1) to implantation of either a sirolimus-eluting bioresorbable polymer stent (MiStent) or an everolimus-eluting durable polymer stent (Xience). Randomisation was done by local investigators via web-based software with random blocks according to centre. The primary endpoint was a non-inferiority comparison of a device-oriented composite endpoint (DOCE)-cardiac death, target-vessel myocardial infarction, or clinically indicated target lesion revascularisation-between the groups at 12 months after the procedure assessed by intention-to-treat. A margin of 4·0% was defined for non-inferiority of the MiStent group compared with the Xience group. All participants were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02385279.Findings: Between March 20, and Dec 3, 2015, we randomly assigned 1398 patients with 2030 lesions; 703 patients with 1037 lesions were assigned to MiStent, of whom 697 received the index procedure, and 695 patients with 993 lesions were asssigned to Xience, of whom 690 received the index procedure. At 12 months, the primary endpoint had occurred in 40 patients (5·8%) in the sirolimus-eluting stent group and in 45 patients (6·5%) in the everolimus-eluting stent group (absolute difference -0·8% [95% CI -3·3 to 1·8], pnon-inferiority=0·0001). Procedural complications occurred in 12 patients (1·7%) in the sirolimus-eluting stent group and ten patients (1·4%) in the everolimus-eluting stent group; no clinical adverse events could be attributed to these dislodgements through a minimum of 12 months of follow-up. The rate of stent thrombosis, a safety indicator, did not differ between groups and was low in both treatment groups.Interpretation: The sirolimus-eluting bioabsorbable polymer stent was non-inferior to the everolimus-eluting durable polymer stent for a device-oriented composite clinical endpoint at 12 months in an all-comer population. MiStent seems a reasonable alternative to other stents in clinical practice.Funding: The European Cardiovascular Research Institute, Micell Technologies (Durham, NC, USA), and Stentys (Paris, France). [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 127915383
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22de+Winter%2C+Robbert+J%2E%22">de Winter, Robbert J.</searchLink><br /><searchLink fieldCode="AR" term="%22Yuki+Katagiri%22">Yuki Katagiri</searchLink><br /><searchLink fieldCode="AR" term="%22Asano%2C+Taku%22">Asano, Taku</searchLink><br /><searchLink fieldCode="AR" term="%22Milewski%2C+Krzysztof+P%2E%22">Milewski, Krzysztof P.</searchLink><br /><searchLink fieldCode="AR" term="%22Lurz%2C+Philipp%22">Lurz, Philipp</searchLink><br /><searchLink fieldCode="AR" term="%22Buszman%2C+Pawel%22">Buszman, Pawel</searchLink><br /><searchLink fieldCode="AR" term="%22Jessurun%2C+Gillian+A%2E+J%2E%22">Jessurun, Gillian A. J.</searchLink><br /><searchLink fieldCode="AR" term="%22Koch%2C+Karel+T%2E%22">Koch, Karel T.</searchLink><br /><searchLink fieldCode="AR" term="%22Troquay%2C+Roland+P%2E+T%2E%22">Troquay, Roland P. T.</searchLink><br /><searchLink fieldCode="AR" term="%22Hamer%2C+Bas+J%2E+B%2E%22">Hamer, Bas J. B.</searchLink><br /><searchLink fieldCode="AR" term="%22Ophuis%2C+Ton+Oude%22">Ophuis, Ton Oude</searchLink><br /><searchLink fieldCode="AR" term="%22Wöhrle%2C+jochen%22">Wöhrle, jochen</searchLink><br /><searchLink fieldCode="AR" term="%22Wyderka%2C+Rafal%22">Wyderka, Rafal</searchLink><br /><searchLink fieldCode="AR" term="%22Cayla%2C+Guillaume%22">Cayla, Guillaume</searchLink><br /><searchLink fieldCode="AR" term="%22Hofma%2C+Sjoerd+H%2E%22">Hofma, Sjoerd H.</searchLink><br /><searchLink fieldCode="AR" term="%22Levesque%2C+Sébastien%22">Levesque, Sébastien</searchLink><br /><searchLink fieldCode="AR" term="%22Żurakowski%2C+Aleksander%22">Żurakowski, Aleksander</searchLink><br /><searchLink fieldCode="AR" term="%22Fischer%2C+Dieter%22">Fischer, Dieter</searchLink><br /><searchLink fieldCode="AR" term="%22Kośmider%2C+Maciej%22">Kośmider, Maciej</searchLink><br /><searchLink fieldCode="AR" term="%22Goube%2C+Pascal%22">Goube, Pascal</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 2/3/2018, Vol. 391 Issue 10119, p431-440. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug-eluting+stents%22">Drug-eluting stents</searchLink><br /><searchLink fieldCode="DE" term="%22Surgical+stents%22">Surgical stents</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22Coronary+disease%22">Coronary disease</searchLink><br /><searchLink fieldCode="DE" term="%22Rapamycin%22">Rapamycin</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+system%22">Cardiovascular system</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Immunosuppressive+agents%22">Immunosuppressive agents</searchLink><br /><searchLink fieldCode="DE" term="%22Longitudinal+method%22">Longitudinal method</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care%22">Medical care</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Myocardial+infarction%22">Myocardial infarction</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Statistical+sampling%22">Statistical sampling</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Blind+experiment%22">Blind experiment</searchLink><br /><searchLink fieldCode="DE" term="%22Acute+coronary+syndrome%22">Acute coronary syndrome</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>MiStent is a drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall. It was developed to overcome the limitation of current durable polymer drug-eluting stents eluting amorphous sirolimus. The clinical effect of MiStent sirolimus-eluting stent compared with a durable polymer drug-eluting stents has not been investigated in a large randomised trial in an all-comer population.<bold>Methods: </bold>We did a randomised, single-blind, multicentre, phase 3 study (DESSOLVE III) at 20 hospitals in Germany, France, Netherlands, and Poland. Eligible participants were any patients aged at least 18 years who underwent percutaneous coronary intervention in a lesion and had a reference vessel diameter of 2·50-3·75 mm. We randomly assigned patients (1:1) to implantation of either a sirolimus-eluting bioresorbable polymer stent (MiStent) or an everolimus-eluting durable polymer stent (Xience). Randomisation was done by local investigators via web-based software with random blocks according to centre. The primary endpoint was a non-inferiority comparison of a device-oriented composite endpoint (DOCE)-cardiac death, target-vessel myocardial infarction, or clinically indicated target lesion revascularisation-between the groups at 12 months after the procedure assessed by intention-to-treat. A margin of 4·0% was defined for non-inferiority of the MiStent group compared with the Xience group. All participants were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02385279.<bold>Findings: </bold>Between March 20, and Dec 3, 2015, we randomly assigned 1398 patients with 2030 lesions; 703 patients with 1037 lesions were assigned to MiStent, of whom 697 received the index procedure, and 695 patients with 993 lesions were asssigned to Xience, of whom 690 received the index procedure. At 12 months, the primary endpoint had occurred in 40 patients (5·8%) in the sirolimus-eluting stent group and in 45 patients (6·5%) in the everolimus-eluting stent group (absolute difference -0·8% [95% CI -3·3 to 1·8], pnon-inferiority=0·0001). Procedural complications occurred in 12 patients (1·7%) in the sirolimus-eluting stent group and ten patients (1·4%) in the everolimus-eluting stent group; no clinical adverse events could be attributed to these dislodgements through a minimum of 12 months of follow-up. The rate of stent thrombosis, a safety indicator, did not differ between groups and was low in both treatment groups.<bold>Interpretation: </bold>The sirolimus-eluting bioabsorbable polymer stent was non-inferior to the everolimus-eluting durable polymer stent for a device-oriented composite clinical endpoint at 12 months in an all-comer population. MiStent seems a reasonable alternative to other stents in clinical practice.<bold>Funding: </bold>The European Cardiovascular Research Institute, Micell Technologies (Durham, NC, USA), and Stentys (Paris, France). [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=127915383
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(17)33103-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 431
    Subjects:
      – SubjectFull: Drug-eluting stents
        Type: general
      – SubjectFull: Surgical stents
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Coronary disease
        Type: general
      – SubjectFull: Rapamycin
        Type: general
      – SubjectFull: Cardiovascular system
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Immunosuppressive agents
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical care
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Myocardial infarction
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Statistical sampling
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Acute coronary syndrome
        Type: general
    Titles:
      – TitleFull: A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: de Winter, Robbert J.
      – PersonEntity:
          Name:
            NameFull: Yuki Katagiri
      – PersonEntity:
          Name:
            NameFull: Asano, Taku
      – PersonEntity:
          Name:
            NameFull: Milewski, Krzysztof P.
      – PersonEntity:
          Name:
            NameFull: Lurz, Philipp
      – PersonEntity:
          Name:
            NameFull: Buszman, Pawel
      – PersonEntity:
          Name:
            NameFull: Jessurun, Gillian A. J.
      – PersonEntity:
          Name:
            NameFull: Koch, Karel T.
      – PersonEntity:
          Name:
            NameFull: Troquay, Roland P. T.
      – PersonEntity:
          Name:
            NameFull: Hamer, Bas J. B.
      – PersonEntity:
          Name:
            NameFull: Ophuis, Ton Oude
      – PersonEntity:
          Name:
            NameFull: Wöhrle, jochen
      – PersonEntity:
          Name:
            NameFull: Wyderka, Rafal
      – PersonEntity:
          Name:
            NameFull: Cayla, Guillaume
      – PersonEntity:
          Name:
            NameFull: Hofma, Sjoerd H.
      – PersonEntity:
          Name:
            NameFull: Levesque, Sébastien
      – PersonEntity:
          Name:
            NameFull: Żurakowski, Aleksander
      – PersonEntity:
          Name:
            NameFull: Fischer, Dieter
      – PersonEntity:
          Name:
            NameFull: Kośmider, Maciej
      – PersonEntity:
          Name:
            NameFull: Goube, Pascal
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 02
              Text: 2/3/2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 391
            – Type: issue
              Value: 10119
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1